MEDICAMEN BIOTECH LTD.-$

Medicamen Biotech Limited has announced that its Board of Directors will convene on November 13, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. The meeting will cover both standalone and consolidated results. Additionally, the company has closed its trading window from October 01, 2026, which will reopen 48 hours after the financial results are declared, in compliance with SEBI's insider trading regulations.

Shivalik Rasayan Limited, along with Growel Remedies Limited (PAC), has acquired 5,00,000 equity shares, representing 3.56% of the total capital, in Medicamen Biotech Limited. This acquisition occurred through the allotment of equity shares upon conversion of fully convertible warrants on a preferential basis. Following this transaction, Shivalik Rasayan Limited's holding in Medicamen Biotech Limited increased from 40.46% to 42.57%. The total equity share capital of Medicamen Biotech Limited post-acquisition is Rs. 14,06,28,150/-.

Medicamen Biotech Limited's Preferential Issue Committee approved the allotment of 5,00,000 Equity Shares upon conversion of 5,00,000 Fully Convertible Warrants. The shares were issued at Rs. 530/- each, raising an aggregate of Rs. 26,50,00,000/- (₹26.50 Crore) in cash. The allotment was made on a preferential basis to Shivalik Rasayan Limited, an entity belonging to the 'Promoter and Promoter Group' category. This allotment increases the company's paid-up equity share capital to Rs. 14,06,28,150/-, comprising 1,40,62,815 equity shares of face value Rs. 10/- each.

Mr. Sanjay Bansal, a Director at Medicamen Biotech Limited, has sold 70,000 equity shares, representing 0.51% of his total holding. Prior to the transaction, he held 1,02,813 equity shares (0.76% of total capital). After the sale, his holding reduced to 32,813 equity shares. The transaction, classified as a 'Sale' under SEBI (PIT) Regulations 2015, occurred on the market between September 28, 2026, and September 30, 2026. The total post-transaction holding is 1,05,42,440 equity shares.

Medicamen Biotech Ltd held its 33rd Annual General Meeting (AGM) on September 26, 2026, conducted via video conferencing. The meeting focused on the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, along with the board and auditor reports. Shareholders also voted on the declaration of a dividend on equity shares. The voting results indicate overwhelming support for all resolutions, with promoters and public shareholders voting in favor. The company also uploaded the AGM proceedings and scrutinizer's report on its website.

Medicamen Biotech Ltd. announced the closure of its trading window for designated persons and their immediate relatives. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the financial results for the quarter and half year ending September 30, 2026, are announced to the stock exchanges. The company will intimate the date of the Board Meeting for approving these financial results in due course. This action is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Medicamen Biotech Ltd has filed its Annual Report for the financial year 2025-26, coinciding with the notice for its 33rd Annual General Meeting (AGM). The AGM will be held on September 26, 2026, via Video Conferencing/Other Audio Visual Means. The report includes the Business Responsibility and Sustainability Report and details the company's strategic progress, including strengthening its oncology division, expanding market presence, and accelerating growth in domestic and international markets. The company has also facilitated remote e-voting for shareholders from September 23 to September 25, 2026.

Medicamen Biotech Ltd has submitted its Integrated Annual Report for the Financial Year 2025-26, as per SEBI regulations. The report includes the notice for the 16th Annual General Meeting (AGM) scheduled for September 29, 2026. The Annual Report and AGM notice are also available on the company's website, www.eightyjewels.in. The filing details the company's performance, vision, mission, and corporate structure, including its board of directors and key managerial personnel. The report covers financial statements like the Balance Sheet, Profit and Loss Statement, and Cash Flow Statement, along with management discussions and auditor's reports.

Medicamen Biotech Ltd has announced its 33rd Annual General Meeting (AGM) will be held on Saturday, September 26, 2026, commencing at 12:00 Noon IST. The meeting will be conducted entirely through Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with Ministry of Corporate Affairs (MCA) circulars. The Notice of the AGM and the Integrated Annual Report for FY 2025-26, including the Business Responsibility and Sustainability Report, are being sent electronically to shareholders. Shareholders have the facility to cast their vote electronically prior to and during the AGM. The remote e-voting period will be from September 23 to September 25, 2026. The cut-off date for determining voting eligibility is September 19, 2026.

Medicamen Biotech Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, in compliance with SEBI regulations. The report details the company's corporate identity, operational activities, and financial performance. Key financial figures for FY 2025-26 include a paid-up capital of ₹13,56,28,150, total turnover of ₹178,84,58,167, and profit after taxes of ₹9,40,86,731. The company reported spending ₹25,20,000 on CSR activities, falling short of the statutory requirement by ₹6,13,024. Medicamen Biotech also disclosed its two subsidiaries, OPAL Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited, and confirmed that its Chairman, Rahul Bishnoi, is responsible for BR policy implementation.